AbbVie is a US pharmaceutical company that was spun off from Abbott in 2013. Its focus areas are immunology (Skyrizi, Rinvoq, formerly Humira), cancer drugs, neuroscience and aesthetic medicine with Botox. Its medicines are sold worldwide. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Pharmaceutical manufacturers · North Chicago, USAfull fact sheet
According to the company, it is a global research-based biopharmaceutical company with a single business segment. Its therapeutic areas are immunology, neuroscience, oncology and aesthetics. Immunology includes Skyrizi, approved among other uses for moderate to severe plaque psoriasis, and Rinvoq, approved among other uses for rheumatoid arthritis. In neuroscience the company markets Vraylar for schizophrenia and Botox Therapeutic, for example for chronic migraine. Important customers also include managed care providers such as pharmacy benefit managers, as well as hospitals and government bodies such as the Medicaid programs; external partners handle parts of manufacturing.
Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
52-week-high breakout · Analysis method
The price of ABBV is currently in no zone of this method. The check runs daily after the market close.
Whether a price will soon reach a zone, you see from Watcher. Plans and pricing
How the zone is formed
What is this? The price closes above the highest high of the last 52 weeks for the first time, on clearly higher volume. New 52-week highs are seen as a sign of strength.
Buy zone: the old high up to 1 ATR above it (retest). Stop: 1.5 ATR below the old high. Targets: 3 and 5 ATR above the old high.
The pattern is valid for at most 15 trading days and expires if the price falls below the stop. This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
AbbVie · Sector Health Care · amounts in USD
Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 20, 2026.
In short
Light yellow: Revenue grew over 5 years (+6.0% per year), more slowly than the sector median.
Light red: Net income (total) shrank over 5 years (−1.7% per year); per share −2.8% per year.
Light yellow: Net margin 6.9%, below the sector median (12.9%).
Light green: Profit in each of the last 10 fiscal years.
Light red: Dividend higher than earnings.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
020B40B60B80B
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 25.6B USD · Net income 6.0B USD · Net margin 23.2%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 28.2B USD · Net income 5.3B USD · Net margin 18.8%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 32.8B USD · Net income 5.7B USD · Net margin 17.4%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 33.3B USD · Net income 7.9B USD · Net margin 23.7%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 45.8B USD · Net income 4.6B USD · Net margin 10.1%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 56.2B USD · Net income 11.5B USD · Net margin 20.5%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 58.1B USD · Net income 11.8B USD · Net margin 20.4%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 54.3B USD · Net income 4.9B USD · Net margin 9.0%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 56.3B USD · Net income 4.3B USD · Net margin 7.6%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 61.2B USD · Net income 4.2B USD · Net margin 6.9%
Margin
23%19%17%24%10%21%20%9%8%7%
RevenueNet incomeNet margin (below)in USD
−5B05B10B15B20B
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 13.9B USD · Net income 1.8B USD · Net margin 12.8%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 14.3B USD · Net income 822.0M USD · Net margin 5.7%
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 12.3B USD · Net income 1.4B USD · Net margin 11.1%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 14.5B USD · Net income 1.4B USD · Net margin 9.5%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 14.5B USD · Net income 1.6B USD · Net margin 10.8%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 15.1B USD · Net income −22.0M USD · Net margin −0.1%
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 13.3B USD · Net income 1.3B USD · Net margin 9.6%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 15.4B USD · Net income 938.0M USD · Net margin 6.1%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 15.8B USD · Net income 186.0M USD · Net margin 1.2%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 16.6B USD · Net income 1.8B USD · Net margin 10.9%
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 15.0B USD · Net income 695.0M USD · Net margin 4.6%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 17.0B USD · Net income 3.6B USD · Net margin 21.3%
Margin
13%6%11%9%11%−0%10%6%1%11%5%21%
Earnings per shareUSD per share
02.004.006.008.00
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 3.63 USD
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 3.30 USD
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 3.66 USD
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 5.28 USD
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 2.72 USD
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 6.45 USD
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 6.63 USD
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 2.72 USD
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 2.39 USD
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 2.36 USD
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share 1.02 USD
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 0.39 USD
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 2.03 USD
Dividend per sharePayout ratio (below)USD per share
02.004.006.008.00
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Dividend per share 2.35 USD · Payout ratio 64.7%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Dividend per share 2.63 USD · Payout ratio 79.7%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Dividend per share 3.95 USD · Payout ratio 107.9%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Dividend per share 4.39 USD · Payout ratio 83.1%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Dividend per share 4.84 USD · Payout ratio 177.9%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Dividend per share 5.31 USD · Payout ratio 82.3%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Dividend per share 5.71 USD · Payout ratio 86.1%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Dividend per share 5.99 USD · Payout ratio 220.2%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Dividend per share 6.29 USD · Payout ratio 263.2%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Dividend per share 6.65 USD · Payout ratio 281.8%
Ratio
65%80%108%83%178%82%86%220%263%282%
Dividend per sharePayout ratio (below)USD per share
00.501.001.502.00
Q3/23Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Dividend per share 1.48 USD · Payout ratio 148.0%
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Dividend per share 1.55 USD · Payout ratio 337.0%
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Dividend per share 1.55 USD · Payout ratio 201.3%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Dividend per share 1.55 USD · Payout ratio 201.3%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Dividend per share 1.55 USD · Payout ratio 176.1%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Dividend per share 1.64 USD · Payout ratio not available
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Dividend per share 1.64 USD · Payout ratio 227.8%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Dividend per share 1.64 USD · Payout ratio 315.4%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Dividend per share 1.64 USD · Payout ratio 1,640.0%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Dividend per share 1.73 USD · Payout ratio 169.6%
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Dividend per share 1.73 USD · Payout ratio 443.6%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Dividend per share 1.73 USD · Payout ratio 85.2%
Ratio
148%337%201%201%176%228%315%1,640%170%444%85%
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 61.2B USD · Net income 4.2B USD · Net margin 6.9%
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light yellow: below sector
+6.0%per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 6.0% per year on average, but more slowly than the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light red: shrinking
−1.7%per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: −2.8% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it fell by 1.7% per year on average. The median company in the sector reached +7.5% per year.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 6.91 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 10.1%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light gray: negative equity
–latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light red: above earnings
282%Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 28%.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light green: profit every year
10 of 10fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
61.2B USD
Revenue vs. prior year
+8.6%
Net income (FY)
4.2B USD
Net income vs. prior year
−1.2%
EPS (FY)
2.36 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
+127.8%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
61.2B
4.2B
6.9%
2.36
6.65
282%
2024
Dec 31, 2024
56.3B
4.3B
7.6%
2.39
6.29
263%
2023
Dec 31, 2023
54.3B
4.9B
9.0%
2.72
5.99
220%
2022
Dec 31, 2022
58.1B
11.8B
20.4%
6.63
5.71
86%
2021
Dec 31, 2021
56.2B
11.5B
20.5%
6.45
5.31
82%
2020
Dec 31, 2020
45.8B
4.6B
10.1%
2.72
4.84
178%
2019
Dec 31, 2019
33.3B
7.9B
23.7%
5.28
4.39
83%
2018
Dec 31, 2018
32.8B
5.7B
17.4%
3.66
3.95
108%
2017
Dec 31, 2017
28.2B
5.3B
18.8%
3.30
2.63
80%
2016
Dec 31, 2016
25.6B
6.0B
23.2%
3.63
2.35
65%
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q2/26
Jun 30, 2026
17.0B
3.6B
21.3%
2.03
1.73
85%
Q1/26
Mar 31, 2026
15.0B
695.0M
4.6%
0.39
1.73
444%
Q4/25
Dec 31, 2025
16.6B
1.8B
10.9%
1.02
1.73
170%
Q3/25
Sep 30, 2025
15.8B
186.0M
1.2%
0.10
1.64
1,640%
Q2/25
Jun 30, 2025
15.4B
938.0M
6.1%
0.52
1.64
315%
Q1/25
Mar 31, 2025
13.3B
1.3B
9.6%
0.72
1.64
228%
Q4/24
Dec 31, 2024
15.1B
−22.0M
−0.1%
−0.02
1.64
–
Q3/24
Sep 30, 2024
14.5B
1.6B
10.8%
0.88
1.55
176%
Q2/24
Jun 30, 2024
14.5B
1.4B
9.5%
0.77
1.55
201%
Q1/24
Mar 31, 2024
12.3B
1.4B
11.1%
0.77
1.55
201%
Q4/23
Dec 31, 2023
14.3B
822.0M
5.7%
0.46
1.55
337%
Q3/23
Sep 30, 2023
13.9B
1.8B
12.8%
1.00
1.48
148%
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Insider purchases and sales on the market over 3, 6 and 12 months
Period
Purchases
Sales
Net
3 months
$00 people
$8.2M1 person
−$8.2M
6 months
$00 people
$8.2M1 person
−$8.2M
12 months
$00 people
$18.9M3 people
−$18.9M
Latest transactions
Aug 14, 2026Donoghoe NicholasOfficerOpen-market sale32,710 shares · $8.2M · SEC
Mar 4, 2026Purdue David RyanOfficerOpen-market sale5,230 shares · $1.2M · SEC
Mar 2, 2026Siatis Perry COfficerOpen-market sale · 10b5-1 plan2,600 shares · $611.7K · SEC
Mar 2, 2026Siatis Perry COfficerOpen-market sale · 10b5-1 plan10,291 shares · $2.4M · SEC
Mar 2, 2026Siatis Perry COfficerOpen-market sale · 10b5-1 plan5,777 shares · $1.3M · SEC
Feb 25, 2026Siatis Perry COfficerOpen-market sale · 10b5-1 plan22,381 shares · $5.1M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +80
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)34.3
Rel. strength 60 d+11.5%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
AbbVie reaches agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ELAHERE® in Platinum-Resistant Ovarian CancerYahoo Finance · Oct 21, 13:01